Dabigatran: potential higher risk of acute coronary event compared to other anticoagulants
How to Cite
OrthoEvidence. Dabigatran: potential higher risk of acute coronary event compared to other anticoagulants. ACE Report. 2013;2(8):26. Available from: https://myorthoevidene.com/AceReport/Report/4431
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trialsArch Intern Med. 2012 Mar 12;172(5):397-402. doi: 10.1001/archinternmed.2011.1666. Epub 2012 Jan 9
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
In this meta-analysis, 7 studies (30,514 participants with atrial fibrillation (AF)) reporting the risk of developing myocardial infarction (MI) or acute coronary syndrome (ACS) from the use of dabigatran etexilate were evaluated. In comparison to warfarin, enoxaparin, or placebo, results indicated that dabigatran was associated with an increased risk of myocardial infarction (MI) and acute corona...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE